摘要
目的:探究与分析乌司他丁联合常规疗法治疗慢阻肺并发Ⅱ型呼吸衰竭的效果及对动脉血气指标的影响。方法:采取随机数字表法对本院2017年1月-2019年12月收治的60例慢阻肺并发Ⅱ型呼吸衰竭患者分组,各30例,常规组进行常规治疗,联合组加用乌司他丁治疗,对比两组临床疗效、治疗前后动脉血气指标、急性生理与慢性健康评分(APACHE-Ⅱ)评分及血清C反应蛋白(CRP)水平,同时观察两组不良反应。结果:联合组的临床总有效率高于常规组,差异有统计学意义(P<0.05)。联合组治疗后与常规组治疗后相比,PaCO2水平较低,PaO2水平较高,SaO2水平较高,APACHE-Ⅱ评分较低,血清CRP水平较低,差异有统计学意义(P<0.05)。两组均无严重不良反应。结论:乌司他丁联合常规疗法治疗慢阻肺并发Ⅱ型呼吸衰竭可获得更好的临床效果,缓解相关临床症状及体征,有效改善动脉血气指标,且治疗期间无明显不良反应,安全性较高。
Objective:To probe into and analyze the effect of Ulinastatin combined conventional therapy for COPD with type Ⅱ respiratory failure and the influence on arterial blood gas index.Method:From January 2017 to December 2019,60 patients with COPD complicated with type Ⅱ respiratory failure in our hospital were divided into two groups by random number table method,each 30 cases,the conventional group took routine treatment,the combined group combined with Ulinastatin on the basis of the conventional group.The clinical curative effect,arterial blood gas index,acute physiology and chronic health evaluation (APACHE-Ⅱ) score and serum C-reactive protein (CRP) level before and after treatment in two groups were compared,at the same time adverse reactions in two groups was observed.Result:The total clinical efficiency of the combined group was higher than that of the conventional group,with statistical significance (P<0.05).After treatment,compared with the conventional group,the combined group had a lower level of PaCO2,a higher level of PaO2,a higher level of SaO2,a lower APACHE-Ⅱ score,and a lower serum CRP level (P<0.05).There was no serious adverse reaction in two groups.Conclusion:Ulinastatin combined conventional therapy to treat COPD with type Ⅱ respiratory failure can obtain better clinical curative effect,alleviate the clinical symptoms and signs,effectively improve the arterial blood gas index,and no obvious adverse reactions during the treatment,the security is higher.
作者
朱丽娟
朱卫敏
ZHU Lijuan;ZHU Weimin(Affiliated Rich Hospital of Nantong University,Nantong 226010,China;不详)
出处
《中外医学研究》
2020年第35期49-51,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH